Grifols | GRFS - Ebitda


Grifols reported EUR482.04M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Alaunos Therapeutics USD -21.02M 1.33M Mar/2021
Arca Biopharma USD -25.07M 5.23M Mar/2025
aTyr Pharma USD 25.85M 52.43M Dec/2025
Bio Path USD -3.21M 631K Mar/2025
Brainstorm Cell Therapeutics USD -3.04M 99K Mar/2025
Capricor Therapeutics USD -27.23M 2.66M Jun/2025
Cara Therapeutics USD -2.39M 3.16M Mar/2025
Esperion Therapeutics USD -9.93M 24.99M Sep/2025
GlaxoSmithKline GBP 3.36B 179M Sep/2025
Grifols EUR 482.04M 7.04M Sep/2025
Immunic USD -22.78M 753K Jun/2024
Infinity Pharmaceuticals USD -10.01M 1.39M Jun/2023
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Nektar Therapeutics USD -31.81M 70K Sep/2023
TherapeuticsMD USD -1.64M 700K Sep/2023